AI Article Synopsis
Article Abstract
Some microbial metabolites can be immunomodulatory, but there is limited understanding of how these contribute to inter-individual variation in response to infection. In a recent study in Science, Steed et al. (2017) show that the bacterial metabolite desaminotyrosine (DAT) increases type I interferon expression, resulting in an improved immune response to influenza infection.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.immuni.2017.09.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Genetic risk factors for COVID-19 and influenza are largely distinct.
Nat Genet
August 2024
Regeneron Genetics Center, Tarrytown, NY, USA.
Article Synopsis
- COVID-19 and influenza are respiratory illnesses caused by different viruses but share some symptoms and clinical risk factors, yet their genetic connections remain poorly understood.
- A study involving over 18,000 influenza cases and nearly 276,000 control subjects found no common genetic risk factors between COVID-19 and influenza, revealing specific gene variants linked only to influenza.
- The research highlights the potential for targeting cell surface receptors involved in viral entry, showing that manipulating specific genes could lead to treatments that prevent both COVID-19 and influenza infections.
Building global preparedness for avian influenza.
Lancet
June 2024
Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.
CCFM1227 Produces Desaminotyrosine to Protect against Influenza Virus H1N1 Infection through the Type I Interferon in Mice.
Nutrients
August 2023
Institute for Fetology, The First Affiliated Hospital of Soochow University, Suzhou 215021, China.
Microbiota-derived desaminotyrosine (DAT) protects the host from influenza by modulating the type I interferon (IFN) response. The aim of this study was to investigate the antivirus effects of a DAT-producing bacteria strain. A comparative genomics analysis and UHPLC Q-Exactive MS were used to search for potential strains and confirm their ability to produce DAT, respectively.
View Article and Find Full Text PDFCapacity and use of diagnostics and treatment for patients with severe acute respiratory infections in the pre-COVID-19 era in district and provincial hospitals in Viet Nam.
Western Pac Surveill Response J
March 2022
World Health Organization Viet Nam Country Office, Hanoi, Viet Nam.
Objective: To describe the burden of severe acute respiratory infection (SARI) and the infrastructure and current practices of SARI management in hospitals in Viet Nam.
Methods: We conducted a short observational study at critical care units (CCUs) in 32 district hospitals and 16 provincial hospitals in five provinces in Viet Nam from March to July 2019. We collected data on hospital equipment and medicines used in SARI management.
A living WHO guideline on drugs for covid-19.
BMJ
September 2020
MAGIC Evidence Ecosystem Foundation, Oslo, Norway
Updates: This is the fourteenth version (thirteenth update) of the living guideline, replacing earlier versions (available as data supplements). New recommendations will be published as updates to this guideline.
Clinical Question: What is the role of drugs in the treatment of patients with covid-19?
Context: The evidence base for therapeutics for covid-19 is evolving with numerous randomised controlled trials (RCTs) recently completed and underway.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!